Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail aims to shrink untreatable liver tumors

NCT ID NCT06679985

Disease control Sponsor: Coherus Oncology, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This Phase 2 trial tests whether adding the experimental drug casdozokitug to a standard immunotherapy combination (toripalimab plus bevacizumab) can safely shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls 72 participants and measures side effects and tumor response. It is currently active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
casdozokitug (CHS-388) combined with toripalimab and bevacizumab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver cancer that cannot be surgically removed.
What could go wrong
This is an early Phase 2 trial with only 72 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to shrink tumors.
Why investors are watching

Coherus Oncology is running a phase 2 trial testing a three-drug combination for a common type of liver cancer. The trial enrolls 72 participants and aims to measure how well the combination controls the disease and to find a safe dose. For a small company, this readout matters because a positive result could support further development of its drug candidate, casdozokitug.

If it works: If the combination shows good disease control with an acceptable safety profile, Coherus could advance the drug to a larger trial. That progress could strengthen the company's pipeline and its position in liver cancer treatment.

If it fails: The trial could fail to show enough benefit or could reveal safety problems, which would likely end this drug's development. Trials at this stage often fail, so a negative result would be a significant setback for a small company with few other products.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Unresectable locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases criteria in cirrhotic participants. * Disease that is not amenable to curative surgical and/or locoregional therapies or progressive disease (PD) after surgical and/or locoregional therapies. * ≥ 1 measurable lesion (per RECIST v1.1) that is untreated. Exclusion Criteria: * Has received prior systemic therapy for HCC. * Has previously received an anti-IL-27 antibody (Ab) or anti-IL-27-targeted therapy. * Has known fibrolamellar HCC histology, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC. * Has moderate or severe ascites. * Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Additional protocol-defined inclusion/exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Bankstown-Lidcombe Hospital

    Bankstown, New South Wales, 2200, Australia

  • Beverly Hills Cancer Center

    Beverly Hills, California, 90211, United States

  • Cancer & Blood Specialty Clinic

    Lakewood, California, 90712, United States

  • Chi Mei Medical Center

    Tainan, 71004, Taiwan

  • China Medical University Hospital

    Taichung, Taichung City, 404, Taiwan

  • Christus St. Vincent Regional Medical Center

    Santa Fe, New Mexico, 87505, United States

  • City of Hope

    Duarte, California, 91010, United States

  • City of Hope at Irvine Lennar

    Irvine, California, 92618, United States

  • Curie Oncology

    Singapore, 329563, Singapore

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York, 10021, United States

  • Humanity & Health Clinical Trial Centre

    Hong Kong, Hong Kong

  • Linear Clinical Research

    Nedlands, 6009, Australia

  • Linkou Chang Gung Memorial Hospital (CGMHLK)

    Taoyuan City, 33305, Taiwan

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic - Scottsdale

    Scottsdale, Arizona, 85259, United States

  • Monash Health

    Melbourne, Victoria, 3168, Australia

  • Montefiore Medical Center

    The Bronx, New York, 10467, United States

  • Mountain States Tumor Institute at St. Luke's Regional Medical Center

    Boise, Idaho, 83712, United States

  • National Cancer Centre Singapore

    Singapore, 168583, Singapore

  • National Cheng Kung University Hospital

    Tainan, Tainan City, 704, Taiwan

  • National Taiwan University Hospital

    Tainan, Taipei City, 100, Taiwan

  • Prince of Wales Hospital

    Shatin, New Territories, Hong Kong

  • Princess Margaret Hospital

    Toronto, Ontario, ON M5G 2C4, Canada

  • Prisma Health Cancer Institute

    Greenville, South Carolina, 29605, United States

  • Queen Mary Hospital

    Hong Kong, Pok Fu Lam, Hong Kong

  • Royal Brisbane and Women's Hospital

    Herston, Brisbane, 4006, Australia

  • Sarcoma Oncology Center

    Santa Monica, California, 90403, United States

  • St Vincent's Hospital Sydney

    Darlinghurst, NSW 2010, Australia

  • Sunnybrook Health Sciences Centre - Bayview Campus

    Toronto, Ontario, ON M4N 3M5, Canada

  • Taipei Veterans General Hospital

    Taipei, Taipei City, 112, Taiwan

  • Tan Tock Seng Hospital

    Singapore, 308433, Singapore

  • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)

    Columbus, Ohio, 43210, United States

  • The Winship Cancer Institute Emory University

    Atlanta, Georgia, 30322, United States

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, 90089, United States

  • UW Carbone Cancer Center - Cancer Connect

    Madison, Wisconsin, 53706, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Arizona - Cancer Center

    Tucson, Arizona, 85719, United States

  • University of Kansas Cancer Center

    Kansas City, Kansas, 66160, United States

  • University of Mississippi Medical Center

    Jackson, Mississippi, 39216, United States

  • University of North Carolina (UNC) - Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

  • University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • UofL Health Brown Cancer Center

    Louisville, Kentucky, 40202, United States

  • Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

  • Virginia Oncology Associates

    Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.